HP and arthritic joint disease: ACEA treatment led to reduced intestinal barrier permeability for FITC-Dextran (FD4) (Fig. 4e), attenuated clinical signs of arthritis (Fig. 4f) along with a reduction in serum zonulin levels (Fig. 4g) as well as no morphological signs of gut inflammation (Fig. 4h).